Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a Phase 3b, randomized, double-blind, placebo-controlled trial supplemental material and plain language summary

Name: Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a Phase 3b, randomized, double-blind, placebo-controlled trial supplemental material and plain language summary
Creator: Howard Sofen
Published: 2024-12-17T17:17:20.314Z
Keywords: Dermatology, Psoriasis

Sofen, Howard; Gebauer, Kurt; Spelman, Lynda; Yamauchi, Paul; Yao, Siu-Long; Nishandar, Tushar; Kopeloff, Iris; Crane, Michael; Gogineni, Ranga; Kothekar, Mudgal; Bagel, Jerry

doi:10.17632/h4s7y7fshf.1

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a Phase 3b, randomized, double-blind, placebo-controlled trial supplemental material and plain language summary

Published: 17 December 2024| Version 1 | DOI: 10.17632/h4s7y7fshf.1

Contributors:

Howard Sofen, Kurt Gebauer, Lynda Spelman, Paul Yamauchi, Siu-Long Yao, Tushar Nishandar, Iris Kopeloff, Michael Crane, Ranga Gogineni, Mudgal Kothekar, Jerry Bagel

Description

This is the supplemental material and plain language summary for the manuscript titled, "Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a Phase 3b, randomized, double-blind, placebo-controlled trial" by Sofen H. et al., 2024.

Files

Funding

Sun Pharma (Japan)

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a Phase 3b, randomized, double-blind, placebo-controlled trial supplemental material and plain language summary

Description

Files

Categories

Funding

Licence